aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT
4D Molecular Therapeutics
4D Molecular Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
5858 Horton St, 455, Emeryville, California 94608, US HQ
2013 Founded
213 Employees
Public company Type
FDMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5858 Horton St, 455, Emeryville, California 94608, US
- Founded
- 2013
- Employees
- 213
- Programs
- 19
- Drugs
- 13
- Patents
- 15
4D Molecular Therapeutics pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
4D Molecular Therapeutics drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in 4D Molecular Therapeutics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to 4D Molecular Therapeutics in public FDA and regional records.
-
Development asset linked to 4D Molecular Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in 4D Molecular Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
covid-19 vaccine (recombinant, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in 4D Molecular Therapeutics's portfolio. Molecular target: Spike glycoprotein.
- Target
- Spike glycoprotein
- Mechanism
- Spike glycoprotein vaccine antigen
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to 4D Molecular Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to 4D Molecular Therapeutics in public FDA and regional records.
-
Development asset linked to 4D Molecular Therapeutics in public FDA and regional records.
-
Development asset linked to 4D Molecular Therapeutics in public FDA and regional records.